Literature DB >> 7581076

1994 Consensus Conference on Acute GVHD Grading.

D Przepiorka1, D Weisdorf, P Martin, H G Klingemann, P Beatty, J Hows, E D Thomas.   

Abstract

Grading acute graft-versus-host disease (GVHD) is usually based on quantification of rash, serum bilirubin and diarrhea. Standard criteria have been developed and used for > 20 years by most transplant centers. However, neither the standard GVHD grading system nor any of several revisions has been validated in the context of GVHD prophylaxis with cyclosporine. The 1994 Consensus Conference on Acute GVHD Grading held in Keystone in January 1994 provided an opportunity to: (1) review data regarding these standard criteria; (2) determine if there are sufficient data to revise these criteria; and (3) develop recommendations for reporting results of GVHD prevention trials. Data were provided for 8249 patients from 12 large transplant centers and 2 transplant registries. Standard GVHD grading criteria were found to distinguish different mortality risks and treatment response rates. Analysis of new data suggested that persistent nausea with histologic evidence of GVHD but no diarrhea be included as stage 1 gastrointestinal GVHD. Additional studies were recommended to evaluate heterogeneity of outcome within GVHD grades prior to making further revisions. To improve comparability between publications, reports of GVHD prevention trials should include an accurate description of the grading system used and should report actuarial rates of grades II-IV and III-IV GVHD corrected for graft failure and potential interventions for early relapse. Additional information should include indications for therapy of GVHD and response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581076

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  1499 in total

1.  Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation.

Authors:  U Machida; M Kami; T Fukui; Y Kazuyama; M Kinoshita; Y Tanaka; Y Kanda; S Ogawa; H Honda; S Chiba; K Mitani; Y Muto; K Osumi; S Kimura; H Hirai
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

Review 2.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

3.  Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation.

Authors:  Alain M Ngoma; Kazuhiko Ikeda; Yuko Hashimoto; Kazuhiro Mochizuki; Hiroshi Takahashi; Hideki Sano; Hayato Matsumoto; Hideyoshi Noji; Syunnichi Saito; Atsushi Kikuta; Kazuei Ogawa; Mikio Ohtsuka; Masafumi Abe; Kenneth E Nollet; Hitoshi Ohto
Journal:  Int J Hematol       Date:  2011-12-14       Impact factor: 2.490

4.  Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.

Authors:  Suman Paul; Marianna Zahurak; Leo Luznik; Richard F Ambinder; Ephraim J Fuchs; Javier Bolaños-Meade; Nina Wagner-Johnston; Lode J Swinnen; Laura Schoch; Ravi Varadhan; Richard J Jones; Douglas E Gladstone
Journal:  Biol Blood Marrow Transplant       Date:  2020-06-24       Impact factor: 5.742

5.  Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Authors:  Sarah Anand; Samantha Thomas; Kelly Corbet; Cristina Gasparetto; Gwynn D Long; Richard Lopez; Ashley K Morris; David A Rizzieri; Keith M Sullivan; Anthony D Sung; Stefanie Sarantopoulos; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-17       Impact factor: 5.742

6.  A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

Authors:  Carolina Martínez-Laperche; Elena Buces; M Carmen Aguilera-Morillo; Antoni Picornell; Milagros González-Rivera; Rosa Lillo; Nazly Santos; Beatriz Martín-Antonio; Vicent Guillem; José B Nieto; Marcos González; Rafael de la Cámara; Salut Brunet; Antonio Jiménez-Velasco; Ildefonso Espigado; Carlos Vallejo; Antonia Sampol; José María Bellón; David Serrano; Mi Kwon; Jorge Gayoso; Pascual Balsalobre; Álvaro Urbano-Izpizua; Carlos Solano; David Gallardo; José Luis Díez-Martín; Juan Romo; Ismael Buño
Journal:  Blood Adv       Date:  2018-07-24

7.  Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?

Authors:  Mitchell Sabloff; Ronald M Sobecks; Kwang Woo Ahn; Xiaochun Zhu; Marcos de Lima; Jennifer R Brown; Yoshihiro Inamoto; H Kent Holland; Mahmoud D Aljurf; Mary J Laughlin; Rammurti T Kamble; Jack W Hsu; Baldeep M Wirk; Matthew Seftel; Ian D Lewis; Mukta Arora; Edwin P Alyea; Matt E Kalaycio; Jorge Cortes; Richard T Maziarz; Robert Peter Gale; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-07       Impact factor: 5.742

8.  Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models.

Authors:  D Kim; H-H Won; S Su; L Cheng; W Xu; N Hamad; J Uhm; V Gupta; J Kuruvilla; H A Messner; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

9.  Acute pancreatitis following allogeneic hematopoietic stem cell transplantation in children.

Authors:  Daichi Sajiki; Daiki Yamashita; Ryo Maemura; Hironobu Kitazawa; Hirotoshi Sakaguchi; Nao Yoshida; Asahito Hama
Journal:  Int J Hematol       Date:  2021-07-21       Impact factor: 2.490

10.  Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children is Associated with Improved Survival.

Authors:  Ashok Srinivasan; Anusha Sunkara; William Mitchell; Sudeep Sunthankar; Guolian Kang; Dennis C Stokes; Saumini Srinivasan
Journal:  Biol Blood Marrow Transplant       Date:  2017-09-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.